Doptelet Sprinkle is a drug owned by Akarx Inc. It is protected by 1 US drug patent filed in 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 28, 2027. Details of Doptelet Sprinkle's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US7638536 | 2-Acylaminothiazole derivative or salt thereof |
Jul, 2027
(1 year, 9 months from now) | Active |
US patents provide insights into the exclusivity only within the United States, but Doptelet Sprinkle is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Doptelet Sprinkle's family patents as well as insights into ongoing legal events on those patents.
Doptelet Sprinkle's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Doptelet Sprinkle's generic launch date based on the expiry of its last outstanding patent is estimated to be Jul 28, 2027 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Doptelet Sprinkle Generics:
There are no approved generic versions for Doptelet Sprinkle as of now.
Alternative Brands for Doptelet Sprinkle
There are several other brand drugs using the same active ingredient (Avatrombopag Maleate) as Doptelet Sprinkle. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Akarx Inc |
|
About Doptelet Sprinkle
Doptelet Sprinkle is a drug owned by Akarx Inc. Doptelet Sprinkle uses Avatrombopag Maleate as an active ingredient. Doptelet Sprinkle was launched by Akarx Inc in 2025.
Approval Date:
Doptelet Sprinkle was approved by FDA for market use on 24 July, 2025.
Active Ingredient:
Doptelet Sprinkle uses Avatrombopag Maleate as the active ingredient. Check out other Drugs and Companies using Avatrombopag Maleate ingredient
Dosage:
Doptelet Sprinkle is available in granule form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 10MG BASE | GRANULE | Prescription | ORAL |